CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,247 enrolled
Drug / intervention
amlodipine / indapamide / perindopril arginine FDCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03722524
NCT03722524N/ACompleted

Multinational Observational Uncontrolled Open Programme "The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy"

Servier Russia·observational·Posted Oct 29, 2018·Updated Jun 10, 2021

In Brief

An observational study evaluating amlodipine / indapamide / perindopril arginine FDC for Arterial Hypertension. Completed, enrolled 1,247 participants across 51 sites.

Detailed Summary

The use of TRIple fixed-dose COmbination in the treatment of arteriaL hypertension: opportunity for effective BP control with cOmbined antihypertensive therapy. The main aim of this study to assess the antihypertensive effectiveness effect on the 24-hour BP profile, as well as tolerability of and compliance to the treatment with a triple FDC of amlodipine / indapamide / perindopril arginine in hypertensive patients in the real clinical practice. Type of program: Multicenter, observational, non-controlled, open-label program. Investigators: Cardiologists and outpatient (primary care) physicians (general practitioners). Number of patients: 1,300 hypertensive patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 29, 2018
Enrollment StartOct 1, 2018
Primary CompletionJul 17, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.7 years ago

Interventions

amlodipine / indapamide / perindopril arginine FDCdrug

CCB / diuretic / ACE inhibitor